Localization of the stem cell markers LGR5 and Nanog in the normal and the cancerous human ovary and their inter-relationship

Acta Histochemica

Volumn 115, Issue 4, 2013, Pages 330-338

  Amsterdam, Abraham ^a   Raanan, Calanit ^a   Schreiber, Letizia ^b   Freyhan, Ora ^a   Schechtman, Lea ^c   Givol, David ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b WOLFSON MEDICAL CENTER   (Israel)

^c HAEMEK MEDICAL CENTER   (Israel)

Author keywords

LGR5; Nanog; Normal and cancerous ovary; Postmenopausal women; Stem cells

Indexed keywords

CELL MARKER; G PROTEIN COUPLED RECEPTOR; LEUCINE RICH REPEAT CONTAINING G PROTEIN COUPLED RECEPTOR 5; TRANSCRIPTION FACTOR NANOG; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY LABELING; ARTICLE; CELLULAR DISTRIBUTION; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MOLECULAR PATHOLOGY; OVARY CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ADULT; AGED; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; MIDDLE AGED; NEOPLASM GRADING; OVARIAN NEOPLASMS; OVARY; POSTMENOPAUSE; RECEPTORS, G-PROTEIN-COUPLED; TUMOR MARKERS, BIOLOGICAL;

EID: 84876334179     PISSN: 00651281     EISSN: 16180372     Source Type: Journal    
DOI: 10.1016/j.acthis.2012.09.004     Document Type: Article

References (48)

1. Ambady S., Malcuit C., Kashpur O., Kole D., Holmes W.F., Hedblom E., et al. Expression of NANOG and NANOGP8 in a variety of undifferentiated and differentiated human cells. Int J Dev Biol 2010, 54:1743-1754.
2. Amsterdam A., Shezen E., Raanan C., Schreiber L., Prus D., Slilat Y., et al. Nuclear localization of phosphorylated ERK1 and ERK2 as markers for the progression of ovarian cancer. Int J Oncol 2011, 39:649-656.
3. Amsterdam A., Shezen E., Raanan C., Slilat Y., Ben-Arie A., Prus D., et al. Epiregulin as a marker for the initial steps of ovarian cancer development. Int J Oncol 2011, 39:1165-2117.
4. Amsterdam A., Shezen E., Raanan C., Schreiber L., Slilat Y., Fabrikant Y., et al. Differential staining of δ-synuclein in poorly differentiated compared to highly differentiated colon cancer cells. Oncol Rep 2012, 27:1451-1454.
5. Amsterdam A., Shezen E., Raanan C., Schreiber L., Slilat Y., Fabrikant Y., et al. Two initiation sites of early detection of colon cancer, revealed by localization of pERK 12; in the nuclei or in aggregates at the perinuclear region of tumor cells. Int J Oncol 2012, 40:782-788.
6. Barker N., Van Es J.H., Kuipers J., Jujala P., van den Born M., Cozijnsen M., et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007, 449:217-229.
7. Barker N., van Es J.H., Jaks V., Kasper M., Snippert H., Toftgård R., et al. Very long-term self-renewal of small intestine, colon, and hair follicles from cycling Lgr5+ve stem cells. Cold Spring Harb Symp Quant Biol 2008, 73:351-356.
8. Bolton K.L., Ganda C., Berchuck A., Pharaoh P.D., Gayther S.A. Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the Ovarian Cancer Association Consortium (OCAC). J Intern Med 2012, 27:366-378.
9. Boman B.M., Huang E. Human colon cancer stem cells: a new paradigm in gastrointestinal oncology. J Clin Oncol 2008, 26:2828-2838.
10. Booth H.A., Holland P.W. Eleven daughters of NANOG. Genomics 2004, 84:229-238.
11. Chambers I., Tomlinson S.R. The transcriptional foundation of pluripotency. Development 2009, 136:2311-2322.
12. Chiou S.H., Wang M.L., Chou Y.T., Chen C.J., Hong C.F., Hsieh W.J., et al. Coexpression of Oct4 and Nanog enhance malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res 2010, 70:10433-10444.
13. Chik F., Szyf M., Rabbani S.A. Role of epigenetics in cancer initiation and progression. Adv Exp Med Biol 2011, 720:91-104.
14. Fairbanks D.J., Maughan P.J. Evolution of the NANOG pseudogene family in the human and chimpanzee genomes. BMC Evol Biol 2006, 6:12.
15. Gidekel S., Pizov G., Bergman Y., Pikarsky E. Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell 2003, 4:361-370.
16. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
17. Jeter C.R., Badeaux M., Choy G., Chandra D., Patrawala L., Liu C., et al. Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells 2009, 27:993-1005.
18. Judkins T, Rosenthal E, Arnell C, Burbidge LA, Geary W, Barrus T, et al. Clinical significance of large rearrangements in BRCA1 and BRCA2. Cancer 2012, , in press. doi:10.1002/cncr.27556.
19. Kernagis D.N., Hall A.H., Datto M.B. Genes with bimodal expression are robust diagnostic targets that define distinct subtypes of epithelial ovarian cancer with different overall survival. J Mol Diagn 2012, 14:214-222.
20. Korinek V., Barker N., Moerer P., van Donselaar E., Huls G., Peters P.J., et al. Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat Genet 1998, 19:379-383.
21. Kuhn E., Kurman R.J., Shih I.M. Ovarian cancer is and imported disease: fact or fiction?. Curr Obstet Gynecol Rep 2012, 11:1-9.
22. Kurman R., Shih L. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer. Shifting the paradigm. Hum Pathol 2011, 42:918-931.
23. Lee H., Park G., Jung J.H., Ahn W.S., Lee J.M., Kim B.K., et al. Diagnostic approach using the expression profiling of the P53 tumor suppressor gene and its related proteins in ovarian epithelial tumors. Int J Gynecol Cancer 2005, 15:453-461.
24. Li H.C., Stoicov C., Rogers A.B., Houghton J. Stem cells and cancer: evidence for bone marrow stem cells in epithelial cancers. World J Gastroenterol 2006, 12:363-371.
25. Li M., He Y., Dubois W., Wu X., Shi J., Huang J. Distinct regulatory mechanisms and functions for p53-activated and p53-repressed DNA damage response genes in embryonic stem cells. Mol Cell 2012, 46:30-42.
26. Lin T., Chao C., Saito S., Mazur S.J., Murphy M.E., Appella E., et al. p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol 2005, 7:65-71.
27. Lobo N.A., Shimono Y., Qian D., Clark M.F. The biology of cancer promotes cell proliferation and tumor formation. Am J Pathol 2007, 173:835-843.
28. Mathieu J., Zhang Z., Zhou W., Wang A.J., Heddleston J.M., Pinna C.M., et al. HIF induces human embryonic stem cell markers in cancer cells. Cancer Res 2011, 71:4640-4652.
29. McCluggage W.G. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology 2011, 43:420-432.
30. Morice P., Uzan C., Fauvet R., Gouy S., Duvillard P., Darai E. Borderline ovarian tumor: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence. Lancet Oncol 2012, 13:e103-e115.
31. Nakagawa M., Yamanaka S. Reprogramming of somatic cells to pluripotency. Adv Exp Med Biol 2010, 695:215-224.
32. Nicolis S.K. Cancer stem cells and " stemness" genes in neuro-oncology. Neurobiol Dis 2007, 25:217-229.
33. Niwa H., Ogawa K., Shimosato D., Adachi K. A parallel circuit of LIF signalling pathways maintains pluripotency of mouse ES cells. Nature 2009, 460:118-122.
34. Pan G., Thomson J.A. Nanog and transcriptional networks in embryonic stem cell pluripotency. Cell Res 2007, 17:42-49.
35. Parte S., Bhartiya D., Telang J., Daithankar V., Salvi V., Zaveri K., et al. Detection, characterization, and spontaneous differentiation in vitro of very small embryonic-like putative stem cells in adult mammalian ovary. Stem Cells Dev 2011, 20:1451-1464.
36. Piestun D., Kochupurakkal B.S., Jacob-Hirsch J., Zeligson S., Koudritsky M., Domany E., et al. Nanog transforms NIH3T3 cells and targets cell-type restricted genes. Biochem Biophys Res Commun 2006, 343:279-285.
37. Po A., Ferretti E., Miele E., De Smaele E., Paganelli A., Canettieri G., et al. Hedgehog controls neural stem cells through p53-independent regulation of Nanog. EMBO J 2010, 29:2646-2658.
38. Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch 2012, 460:237-249.
39. Prud'homme G.J. Cancer stem cells and novel targets for antitumor strategies. Curr Pharm Des 2012, 18(19):2838-2849.
40. Radtke F., Clevers H. Self-renewal and cancer of the gut: two sides of a coin. Science 2005, 307:1904-1909.
41. Saad A.F., Hu W., Sood A.K. Microenvironment and pathogenesis of epithelial ovarian cancer. Horm Cancer 2010, 1:277-290.
42. Serrano-Olvera A., Duenas-Gonzalez A., Gallardo-Rincon D., Candelaria M., De la Garza-Salazar J. Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treat Rev 2006, 32:180-190.
43. Tay Y.M., Tam W.L., Ang Y.S., Gaughwin P.M., Yang H., Wang W., et al. MicroRNA-134 modulates the differentiation of mouse embryonic stem cells, where it causes post-transcriptional attenuation of Nanog and LRH1. Stem Cells 2008, 26:17-29.
44. Vallier L., Mendjan S., Brown S., Chng Z., Teo A., Smithers L.E., et al. Activin/nodal signalling maintains pluripotency by controlling Nanog expression. Development 2009, 136:1339-1349.
45. Visvanathan K., Vang R., Shaw P., Gross A., Soslow R., Parkash V., et al. Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study. Am J Surg Pathol 2011, 35:1766-1775.
46. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008, 8:755-768.
47. Wilken J.A., Badri T., Cross S., Raji R., Santin A.D., Schwartz P., et al. EGFR/HER-targeted therapeutics in ovarian cancer. Future Med Chem 2012, 4:447-469.
48. Zhang J., Wang X., Li M., Han J., Chen B., Wang B., et al. NANOGP8 is a retrogene expressed in cancers. FEBS J 2006, 273:1723-1730.